Bridging the critical policy-practice gap in radical treatment of vivax malaria in Afghanistan

In Afghanistan, Plasmodium vivax malaria remains a significant problem, but the key to reduction of transmission, the anti-hypnozoite drug primaquine, is not routinely prescribed because of fears of haemolysis in patients with G6PD deficiency, a common genetic condition in Afghanistan. Novel rapid diagnostic test devices are now available which identify deficient individuals with a high level of sensitivity in detailed studies. However, the outcome of introducing this test (and primaquine treatm ent resulting from it) across the health system is unclear.

Drug-based Strategies
P. vivax

Mar 2016 — Mar 2019

$301,522

Afghanistan